Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599

W. Zhang,Suzanne E. Dahlberg,D. Yang,Alan Sandler,J. R. Brahmer,Joan H. Schiller,David P. Carbone,David H. Johnson,H Lenz

Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599

2009

W. Zhang
Suzanne E. Dahlberg
D. Yang
Alan Sandler
J. R. Brahmer
Joan H. Schiller
David P. Carbone
David H. Johnson
H Lenz

8032 Background: E4599 was a randomized phase III study which demonstrated a survival advantage in advanced NSCLC pts treated with bevacizumab (bev) + carboplatin/paclitaxel (BPC) versus carboplati...

Keywords:

Carboplatin
Bevacizumab
Pharmacogenetic Analysis
Angiogenesis Pathway
Paclitaxel
Oncology
Internal medicine
Medicine
genetic variants

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations